Two new classifications for myeloid neoplasms were introduced in 2022: the International Consensus Classification (ICC) and the 5th edition WHO Classification (WHO-HAEM5). Both classifications build ...
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma Therapy-related myeloid neoplasm (t-MN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results